June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPE Cells
Author Affiliations & Notes
  • Ping Yang
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Rose Trimpey-Warhaftig
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Jin Mo Koo
    Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, United States
  • John Park
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Hampar Karageozian
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Vicken H Karageozian
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Zixuan Shao
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Glenn J Jaffe
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Ping Yang None; Rose Trimpey-Warhaftig None; Jin Mo Koo None; John Park Allegro Ophthalmics, LLC, Code E (Employment); Hampar Karageozian Allegro Ophthalmics, LLC, Code E (Employment); Vicken Karageozian Allegro Ophthalmics, LLC, Code E (Employment); Zixuan Shao Allegro Ophthalmics, LLC, Code E (Employment); Glenn Jaffe None
  • Footnotes
    Support  This work was supported, in part, by Unrestricted Research to Prevent Blindness Grant and the NIH Core Grant [P30EY005722].
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3041 – F0412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ping Yang, Rose Trimpey-Warhaftig, Jin Mo Koo, John Park, Hampar Karageozian, Vicken H Karageozian, Zixuan Shao, Glenn J Jaffe; Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPE Cells. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3041 – F0412.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Risuteganib (RSG) is a synthetic peptide that has shown promising efficacy in an intermediate dry age-related macular degeneration (AMD) phase 2 clinical study. We previously reported that RSG protected against retinal pigment epithelial (RPE) cell injury induced by hydroquinone (HQ), a major oxidant in cigarette smoke and atmospheric pollutants agents implicated in AMD pathogenesis. Herein, we investigate whether RPE cells take up RSG.

Methods : Cultured human RPE cells were transduced overnight with late endosome-GFP, mitochondria-GFP, or endoplasmic reticulum-GFP using CellLight Reagents (BacMam 2.0) at 40 particles per cell. Cells were washed, incubated with Alexa Fluor™ 555 alkyne, triethylammonium salt (AF555, 50uM, control) or RSG-Alexa Fluor™ 555 (RSG-AF555, 50uM, synthesized using Fmoc [the fluorenylmethoxycarbonyl protecting group] solid-phase peptide synthesis and N-Hydroxysuccinimidyl ester-amine reaction) for various times at 37°C or for 2.5 hours at 4°C. RSG co-localization with cell organelles were examined by confocal microscopy.

Results : A large amount of cytoplasmic dot-like staining was detected in RSG-AF555-treated cells while little staining was seen in AF555-treated cells 2.5 hours post-treatment. The cytoplasmic dot-like staining pattern in RSG-AF555-treated cells was dramatically reduced at 4°C when compared to 37°C at 2.5 hours post-treatment. RSG-AF555 accumulated in the cells as early as 30 minutes and remained for at least 21 hours. In RSG-AF555-treated cells, some RSG-AF555 dots were co-stained with late endosome and additional RSG-AF555 dots were co-stained with mitochondrial and endoplasmic reticulum 2.5 hours post-treatment.

Conclusions : Experiments at temperatures that permit and inhibit endocytosis suggest that cultured RPE cells take up RSG via endocytosis. Co-localization of RSG with cell organelles may be involved in RSG’s protection against HQ-induced cell damage.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×